ClinicalTrials.gg

von Willebrand Diseases clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 96 studies for von Willebrand Diseases across more than 10 countries. 25 are recruiting or about to start. 81 of them are mainly about von Willebrand Diseases (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13.

Status

Completed
51
Recruiting
23
Status unknown
8
Terminated
6
Withdrawn
4
Active, not recruiting
2

Phase

Phase 3
19
Phase 2
13
Phase 1
5
Phase 4
4

Where

United States
38
France
20
United Kingdom
18
Germany
17
Italy
13
Austria
11

Who develops what

Add von Willebrand Diseases to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 6 programs from 5 companies, 6 with this as their studies’ main aim; 3 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Takeda, Alnylam Pharmaceuticals and Incyte here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
vonicog alfaApproved: EU 2018☆ Track2 live phase-3 studies: NCT05582993, NCT07129343Takeda
antihemophilic factor, human recombinantApproved: EU 2004☆ Track1 live phase-3 study: NCT07129343Takeda
latarcibart☆ Track1 live phase-3 study: NCT07115004Incyte Corporation

The 3 in phase 3 with the nearest primary completion, of 6 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 30 Jun 2027 est.ALN-6400 · Alnylam Pharmaceuticals · Phase 2 main aimNCT07575308 HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB — primary endpoint: Frequency of Adverse Events · 24 enrolled
  • Jul 2027 est.blumiciment · Hemab ApS · Phase 2 main aimNCT06754852 A Study Assessing HMB-002 in Participants With Von Willebrand Disease — primary endpoint: Incidence of Treatment emergent adverse events (TEAE) · 108 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in von Willebrand Diseases studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

8studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 8, phase 3 first

Who these studies take

Of the 23 von Willebrand Diseases studies recruiting now, 15 (65%) set no upper age limit and 8 (35%) stop at 75 or younger. 14 (61%) take children under 18. 4 (17%) are for women only and 0 (0%) for men only; 3 (13%) take healthy volunteers.

Recruiting studies that take each age, of 23
AgeWomenMen
108 (35%)7 (30%)
1821 (91%)17 (74%)
3020 (87%)17 (74%)
4020 (87%)17 (74%)
5019 (83%)17 (74%)
6518 (78%)16 (70%)
7516 (70%)14 (61%)
8515 (65%)13 (57%)

Across all 96 studies, recruiting or not: 31% stop at 75 or younger and 24% at 65; 57% take children; 11% are for women only and 0% for men only; 14% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long von Willebrand Diseases studies take

Of 24 observational studies under von Willebrand Diseases, half reached primary completion within 71 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Observational71 mo45–97 · 24 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 96. Browse all 96 → or search them.